RAPT Therapeutics, Inc. (RAPT) Share-based Compensation (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Share-based Compensation for 5 consecutive years, with $4.6 million as the latest value for Q4 2024.
- Quarterly Share-based Compensation rose 3.61% to $4.6 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $19.9 million through Dec 2024, up 16.64% year-over-year, with the annual reading at $19.9 million for FY2024, 16.64% up from the prior year.
- Share-based Compensation hit $4.6 million in Q4 2024 for RAPT Therapeutics, up from $4.6 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.4 million in Q1 2024 to a low of $2.0 million in Q3 2020.
- Historically, Share-based Compensation has averaged $3.3 million across 5 years, with a median of $2.9 million in 2021.
- Biggest five-year swings in Share-based Compensation: dropped 18.45% in 2021 and later soared 58.65% in 2023.
- Year by year, Share-based Compensation stood at $2.6 million in 2020, then fell by 18.45% to $2.1 million in 2021, then surged by 45.01% to $3.0 million in 2022, then skyrocketed by 46.41% to $4.4 million in 2023, then grew by 3.61% to $4.6 million in 2024.
- Business Quant data shows Share-based Compensation for RAPT at $4.6 million in Q4 2024, $4.6 million in Q3 2024, and $5.4 million in Q2 2024.